HDAC9 and Parkinson disease: Although the neuroprotective phenotype of HDAC selective, such as SIRT 2, inhibitors have been demonstrated in vivo in animal models of PD, thus far pathogenic histone hypoacetylation and transcriptional dysfunction in the nigrostriatal of PD is yet to be confirmed.